# Clinical Efficacy of Tofacitinib in Treating Granulomatous Reaction After Mesotherapy: A Case Series Analysis

## TL;DR

Tofacitinib is effective and safe for treating skin reactions caused by cosmetic mesotherapy injections.

## Contribution

Demonstrates tofacitinib's efficacy in treating granulomatous reactions post-mesotherapy in a clinical case series.

## Key findings

- Six patients showed significant improvement in skin lesions after tofacitinib treatment.
- No treatment-related adverse events were observed during follow-up.
- Tofacitinib is a viable option for managing inflammatory granulomatous reactions.

## Abstract

Mesotherapy, a widely utilized minimally invasive cosmetic procedure, carries potential risks of adverse reactions due to non‐standardized protocols and overuse. Delayed granulomatous reactions represent a chronic complication, imposing significant physical and psychological burdens on patients.

This case series aims to evaluate the efficacy and safety of tofacitinib in managing non‐infectious granulomatous reactions following mesotherapy.

This retrospective analysis included six patients diagnosed with non‐infectious granulomatous reactions post‐mesotherapy, treated at Peking Union Medical College Hospital between October 2021 and April 2025. All patients received oral tofacitinib. Clinical outcomes, treatment regimens, and safety profiles were assessed.

All six patients demonstrated significant improvement in skin lesion severity, with no treatment‐related adverse events observed during follow‐up.

Oral tofacitinib exhibits promising clinical efficacy and a favorable safety profile for non‐infectious granulomatous reactions induced by mesotherapy, positioning it as a viable therapeutic option during the inflammatory phase.